BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $12.00

BioCryst Pharmaceuticals (NASDAQ:BCRX - Free Report) had its price target upped by Evercore ISI from $10.00 to $12.00 in a research report sent to investors on Monday,Benzinga reports. They currently have an outperform rating on the biotechnology company's stock.

BCRX has been the subject of a number of other reports. Barclays increased their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 5th. Needham & Company LLC increased their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Monday. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $15.17.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock traded up $0.26 during trading hours on Monday, reaching $7.93. The company had a trading volume of 2,689,586 shares, compared to its average volume of 2,475,698. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -13.00 and a beta of 1.76. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.88. The company has a 50-day moving average price of $7.59 and a 200 day moving average price of $7.59.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analysts' expectations of $113.99 million. The firm's quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.19) earnings per share. As a group, research analysts expect that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Deerfield Management Company L.P. Series C raised its holdings in BioCryst Pharmaceuticals by 62.9% in the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company's stock worth $50,279,000 after purchasing an additional 3,140,804 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock worth $36,776,000 after acquiring an additional 127,708 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock worth $25,369,000 after acquiring an additional 481,359 shares in the last quarter. Two Sigma Advisers LP lifted its position in BioCryst Pharmaceuticals by 13.6% during the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company's stock valued at $16,576,000 after acquiring an additional 261,500 shares during the period. Finally, Rice Hall James & Associates LLC boosted its stake in BioCryst Pharmaceuticals by 4.0% during the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock worth $16,444,000 after acquiring an additional 84,102 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.